First Tracks Biotherapeutics screens with attractive valuation and strong price momentum, but weak business quality and extreme insider selling are significant red flags that warrant exiting the position.
Thesis pillars
- Value Trap Margin Compression↑Improving
- Extreme Insider Selling→Stable
- Quality Below Engine Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026
First Tracks Biotherapeutics, I (TRAX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $45.72: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.20; Below-average business quality.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta... Read more
Sell if holding. Engine safety override at $45.72: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.20; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — First Tracks Biotherapeutics, I
Latest news
- NEWS Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90 — benzinga Oct 16, 2026 positive
- NEWS First Tracks Biotherapeutics Announces ~$200M Private Placement Of 6,106,870 Shares At $32.75/Share To Institutional Inv — benzinga Oct 15, 2026 neutral
- NEWS Canaccord Genuity Maintains Buy on First Tracks, Raises Price Target to $60 — benzinga Oct 13, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on First Tracks, Raises Price Target to $70 — benzinga Oct 13, 2026 positive
- NEWS Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $70 — benzinga Oct 13, 2026 positive
Generated 2026-10-29T11:14:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Volatile — 7.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $45.72: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.20; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $42.52. Score 5.6/10, moderate confidence.
Analyst target: $64.53 (+41.1% upside). Prior stop was $42.52. Stop-loss: $42.52.
Quality below floor (2.5 < 4.0).
First Tracks Biotherapeutics, I trades at a P/E of N/A (forward -12.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover TRAX with a consensus score of 4.3/5. Average price target: $74.
What does First Tracks Biotherapeutics, I do?First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology...
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.